present
report
constitut
attempt
improv
modifi
exist
clinic
evalu
method
new
antimicrobi
agent
treat
respiratori
infect
one
year
ago
gener
guidelin
clinic
evalu
antimicrobi
agent
treat
respiratori
infect
draft
japanes
leav
scope
critic
discuss
translat
english
major
chang
report
respiratori
infect
discuss
head
acut
respiratori
tract
infect
pneumonia
acut
exacerb
chronic
pulmonari
diseas
standard
criteria
set
assess
sever
infect
effect
antimicrobi
agent
question
sever
evalu
basi
combin
assess
sever
infect
sever
clinic
condit
patient
clinic
effect
antimicrobi
agent
use
evalu
basi
clinic
outcom
well
microbiolog
outcom
trial
bodi
temperatur
local
pain
cough
chang
sputum
qualiti
peripher
white
blood
cell
count
creactiv
protein
level
chest
radiograph
use
paramet
evalu
maintain
qualiti
specimen
examin
geckler
classif
specimen
use
report
construct
base
analysi
larg
amount
materi
collect
year
incorpor
intern
extern
factor
concern
present
evalu
method
newli
suggest
standard
criteria
clinic
evalu
new
antimicrobi
drug
expect
practic
properli
hereupon
subject
improv
necessari
committe
clinic
evalu
method
new
antimicrobi
agent
establish
gener
meet
japan
societi
chemotherapi
june
conclud
special
meet
held
aim
intern
harmon
japan
unit
state
europ
area
clinic
evalu
antimicrobi
agent
guidelin
usa
europ
present
meet
show
conform
first
intern
confer
harmon
ich
held
brussel
belgium
howev
japan
guidelin
issu
ministri
health
welfar
known
good
clinic
practic
gcp
went
effect
februari
background
home
abroad
director
japan
societi
chemotherapi
masatoshi
konno
establish
committe
clinic
evalu
method
new
antimicrobi
agent
special
committe
societi
one
reason
establish
special
committe
despit
advanc
level
technic
develop
clinic
evalu
method
new
antimicrobi
agent
treat
respiratori
infect
report
committe
respiratori
system
japan
societi
chemotherapi
produc
antimicrobi
agent
japan
clinic
evalu
new
antimicrobi
agent
necessarili
accept
rest
world
high
time
japan
establish
clinic
evalu
method
antimicrobi
agent
incorpor
viewpoint
intern
harmon
committe
clinic
evalu
method
new
antimicrobi
agent
consist
three
separ
committe
committe
respiratori
system
committe
urinari
system
committe
prevent
postop
infect
intern
meet
held
gener
meet
japanes
societi
chemotherapi
aim
intern
harmon
clinic
evalu
antimicrobi
therapi
mr
ragnar
norrbi
sweden
repres
committe
european
guidelin
mr
murray
lumpkin
food
drug
administr
fda
unit
state
mr
william
r
darrow
schere
plough
research
institut
unit
state
guest
speaker
behalf
japan
three
subcommitte
chairmen
committe
clinic
evalu
method
new
antimicrobi
agent
announc
committe
report
meet
author
report
belong
committe
respiratori
system
committe
respiratori
system
guid
principl
intern
harmon
organ
regular
meet
draft
gener
guidelin
clinic
evalu
antimicrobi
agent
light
issu
fda
usa
infecti
diseas
societi
america
idsa
next
step
investig
variou
viewpoint
order
establish
guidelin
clinic
evalu
method
new
antimicrobi
agent
treat
respiratori
infect
report
attempt
describ
discuss
relev
detail
method
adapt
clinic
evalu
antimicrobi
agent
use
treat
respiratori
infect
clinic
evalu
method
new
antimicrobi
agent
treat
respiratori
infect
outlin
basi
need
intern
harmon
also
conform
japanes
good
clinic
practic
gcp
standard
guidelin
idsa
involv
bacteri
infect
five
respiratori
organ
precis
streptococc
pharyng
tonsil
otiti
media
paranas
sinus
bronchiti
pneumonia
howev
japan
otiti
media
paranas
sinus
commonli
dealt
field
ear
nose
throat
ent
rather
consid
respiratori
diseas
take
consider
respiratori
infect
classifi
three
group
acut
upper
respiratori
tract
infect
includ
acut
tonsil
acut
pharyng
acut
bronchiti
peritonsillar
abscess
retropharyng
abscess
pneumonia
acut
exacerb
chronic
pulmonari
diseas
classif
appropri
clinic
evalu
antimicrobi
agent
particularli
phase
ii
iii
trial
also
appli
phase
iv
trial
infect
mention
particular
suppur
pulmonari
diseas
lung
abscess
empyema
trial
undertaken
respect
standard
establish
criteria
select
patient
clinic
trial
set
object
better
evalu
effect
trial
drug
regard
sever
patient
clinic
condit
sever
infect
consid
care
particular
diseas
entiti
individu
pattern
likewis
differ
standard
select
patient
acut
upper
respiratori
tract
infect
underli
diseas
could
impair
clinic
effect
trial
drug
thu
standard
made
group
basi
sever
infect
without
consid
underli
diseas
far
group
eg
pneumonia
acut
exacerb
chronic
pulmonari
diseas
concern
sever
clinic
condit
determin
combin
sever
infect
underli
diseas
complic
gener
sever
patient
clinic
condit
larg
influenc
underli
diseas
sever
make
difficult
properli
evalu
antimicrobi
drug
trial
therefor
suggest
exclud
patient
consid
sever
clinic
evalu
effect
antimicrobi
agent
trial
evalu
basi
microbiolog
effect
clinic
effect
paramet
use
cours
etiolog
agent
speed
improv
sign
symptom
evalu
done
two
time
point
day
treatment
convent
trial
drug
use
administ
day
recogn
patient
requir
day
treatment
except
accord
present
standard
drug
administr
discontinu
etiolog
agent
consid
erad
day
treatment
basi
clinic
microbiolog
evalu
subsequ
followup
necessari
degre
leeway
allow
regard
test
perform
predetermin
protocol
evalu
microbiolog
effect
conduct
per
gener
guidelin
clinic
evalu
antimicrobi
drug
standard
record
protocol
advanc
clinic
effect
evalu
object
standard
divid
two
categori
effect
effect
instead
extrem
effect
slightli
effect
addit
clinic
effect
evalu
reason
remark
evalu
possibl
record
comprehens
evalu
conduct
basi
clinic
effect
microbiolog
effect
safeti
object
subject
advers
effect
test
abnorm
evalu
method
standard
determin
particular
diseas
must
prerecord
protocol
evalu
safeti
conduct
accord
gener
guidelin
clinic
evalu
antiinfect
drug
evalu
standard
advers
reaction
clinic
test
result
abnorm
clinic
trial
patient
treat
antimicrobi
agent
gener
evalu
effect
antimicrobi
agent
done
end
treatment
eot
infect
may
flare
may
recur
eot
even
though
trial
drug
thought
effect
initi
reason
physic
examin
laboratori
test
perform
defin
time
period
eot
final
evalu
indic
end
studi
eo
respiratori
infect
appropri
time
period
suggest
week
concept
diseas
indic
clinic
evalu
antimicrobi
agent
acut
upper
respiratori
tract
infect
cover
rang
ill
common
cold
acut
bronchiti
acut
bronchiti
infect
inflamm
respiratori
tract
extend
downward
glotti
lower
respiratori
tract
infect
also
share
characterist
includ
pathophysiolog
upper
respiratori
tract
infect
clinic
evalu
oral
antimicrobi
agent
undertaken
patient
acut
tonsil
acut
pharyng
acut
laryngopharyng
acut
bronchiti
peritonsillar
abscess
includ
sever
crypttonsil
peritonsillar
inflamm
retropharyng
abscess
subject
trial
inject
antimicrobi
agent
infect
accompani
underli
chronic
respiratori
diseas
classifi
separ
upper
respiratori
tract
infect
start
initi
common
cold
frequent
infect
descend
involv
lower
respiratori
tract
primari
etiolog
agent
encount
common
cold
often
virus
viral
pathogen
rhinoviru
coronaviru
influenza
viru
adenoviru
coxackieviru
respiratori
syncyti
viru
particular
predilect
respiratori
tract
secondari
bacteri
infect
may
result
involv
lower
respiratori
tract
howev
distribut
infecti
pathogen
vari
accord
site
involv
acut
tonsil
peritonsillar
abscess
pathogen
hemolyt
streptococcu
haemophillu
influenza
staphylococcu
aureu
streptococcu
pneumonia
order
frequenc
acut
pharyng
commonli
encount
bacteria
pneumonia
h
influenza
hemolyt
streptococcu
aureu
among
etiolog
agent
acut
bronchiti
pneumonia
h
influenza
frequent
seen
follow
moraxella
branhamella
organ
aureu
hemolyt
streptococcu
lower
frequenc
occurr
mycoplasma
upper
respiratori
tract
infect
common
preval
period
addit
chlamydia
chlamydia
psittaci
chlamydia
pneumonia
also
involv
acut
respiratori
tract
infect
patient
infect
one
pathogen
diagnos
bacteriolog
examin
highli
suspect
infect
still
confirm
appropri
subject
includ
clinic
trial
new
antimicrobi
agent
patient
insignific
microbiolog
test
result
sign
symptom
acut
respiratori
tract
infect
high
wbc
count
product
cough
purul
natur
also
suitabl
inclus
trial
mycoplasma
chlamydia
infect
host
respons
well
physic
evid
mild
interestingli
recoveri
also
slow
even
treatment
antimicrobi
agent
patient
standard
inclus
evalu
trial
set
separ
import
determin
etiolog
agent
patient
respiratori
infect
select
subject
trial
clinic
evalu
new
antimicrobi
agent
import
commonli
use
method
identifi
infecti
pathogen
microscop
examin
smear
cultur
specimen
appropri
media
sampl
collect
steril
cotton
swab
administr
antimicrobi
agent
commenc
swab
scratch
along
posterior
pharyng
wall
uvula
surfac
suppur
tonsil
patient
pharyng
tonsil
respect
collect
sampl
sampl
cultur
appropri
medium
eg
blood
agar
medium
h
acut
bronchiti
sampl
obtain
purul
area
sputum
cultur
describ
sampl
may
contamin
normal
flora
upper
respiratori
tract
exclud
avoid
probabl
error
evalu
specimen
leucocyt
less
epitheli
cell
per
visual
field
magnif
extrem
like
expector
lesion
probabl
identif
etiolog
agent
also
extrem
high
specimen
satisfi
condit
identif
etiolog
pathogen
less
like
thereacut
tonsil
redden
swell
tonsil
pustul
surfac
acut
pharyng
local
pain
redden
swell
uvula
throat
purul
exud
mani
patient
exhibit
typic
featur
acut
bronchiti
chest
pain
cough
often
product
purul
cardin
featur
diagnosi
acut
upper
respiratori
tract
infect
depend
isol
pathogen
bacteria
suitabl
specimen
patient
characterist
featur
appropri
site
involv
case
failur
identifi
signific
bacteria
microbiolog
test
clinic
patholog
find
consid
collect
diagnosi
leukocyt
count
higher
crp
mgdl
higher
purulentproduct
cough
orexud
present
obviou
patholog
bacteri
viral
origin
sometim
erythrocyt
sediment
rate
esr
accessori
valu
although
increas
mani
condit
therefor
perform
diagnost
test
diagnosi
acut
respiratori
tract
infect
mycoplasma
chlamydia
rel
difficult
contrast
pneumonia
fairli
reliabl
diagnosi
made
help
chest
xray
laboratori
test
reveal
reduc
wbc
count
mani
patient
lead
confus
viral
infect
cultur
method
well
practic
reliabl
diagnosi
need
detect
antibodi
titer
specif
antigen
dna
pathogen
serum
precis
fourfold
higher
increas
mycoplasma
antibodi
titer
observ
blood
sampl
taken
onset
diseas
convalesc
period
usual
week
rise
time
higher
time
higher
complement
fixat
cf
indirect
hemagglutin
iha
antibodi
titer
respect
singl
sampl
diagnost
mycoplasma
infect
similarli
chlamydia
infect
fourfold
higher
rise
cf
antibodi
pair
serum
sampl
higher
increas
singl
sampl
diagnost
chlamydia
infect
detect
antibodi
dna
serum
fluoresc
antibodi
techniqu
enzym
antibodi
techniqu
dna
probe
polymeras
chain
reaction
pcr
techniqu
also
use
altern
diagnost
test
mycoplasma
chlamydia
infect
target
subject
clinic
evalu
antimicrobi
agent
satisfi
criterion
least
two
criteria
describ
suspect
etiolog
agent
isol
suitabl
specimen
strong
possibl
presenc
patient
good
sampl
obtain
observ
magnif
b
transtrach
aspir
method
use
patient
granulocytopenia
fore
qualiti
control
specimen
import
refer
geckler
et
al
tabl
ogihara
classif
use
guidanc
demonstr
bacteria
within
phagocyt
cell
neutrophil
macrophag
particular
specimen
best
evid
establish
diagnosi
sampl
store
futur
reevalu
variou
method
use
cultur
test
sputum
includ
wash
cultur
method
quantit
cultur
method
combin
one
method
anoth
procedur
yield
higher
probabl
detect
etiolog
agent
detect
quantit
cultur
method
microbi
pathogen
cfuml
specimen
indic
organ
etiolog
agent
organ
present
number
lower
ml
specimen
obtain
follow
standard
procedur
minim
amount
normal
oral
flora
contamin
may
also
etiolog
agent
cultur
continu
h
case
absenc
visibl
coloni
cultur
demand
special
condit
exampl
carbon
dioxid
ga
cultur
yield
higher
detect
frequenc
hemolyt
streptococcu
even
though
diagnosi
quick
diagnost
kit
perform
pathogen
cultur
test
method
still
depend
must
perform
confirm
diagnosi
similarli
mycoplasma
chlamydia
infect
diagnosi
done
serolog
test
better
confirm
find
cultur
test
ongo
trial
antimicrobi
agent
common
sign
symptom
acut
bacteri
upper
respiratori
tract
infect
fever
purul
product
cough
pustul
abscess
upper
respiratori
tract
reason
conclud
suppur
inflammatori
condit
present
white
blood
cell
count
rise
higher
migrat
nuclei
left
increas
creactiv
protein
crp
mgdl
higher
discrimin
viral
condit
fever
accompani
mucoid
exud
sputum
mild
increas
crp
leukopenia
mani
patient
characterist
featur
individu
diseas
may
summar
list
pustul
purul
exud
purul
sputum
even
though
etiolog
agent
confirm
white
blood
cell
count
stab
leukocyt
crp
mgdl
valu
exce
maximum
valu
facil
bodi
temperatur
target
subject
clinic
evalu
antimicrobi
drug
mycoplasma
chlamydia
infect
sign
symptom
describ
previou
section
acut
bacteri
upper
respiratori
tract
infect
must
satisfi
criterion
least
three
remain
six
criteria
describ
fourfold
higher
increas
mycoplasma
antibodi
titer
pair
serum
sampl
time
higher
increas
cf
antibodi
titer
time
higher
increas
ha
titer
singl
serum
sampl
patient
exhibit
fourfold
higher
increas
chlamydia
antibodi
titer
pair
serum
sampl
time
higher
increas
cf
antibodi
titer
singl
sampl
patient
test
posit
mycoplasma
chlamydia
antigen
gene
detect
techniqu
describ
howev
mani
patient
result
relat
criterion
avail
week
commenc
treatment
thu
patient
satisfi
standard
criteria
also
includ
trial
patient
exclud
immedi
treat
anoth
suitabl
antimicrobi
agent
furthermor
care
taken
avoid
misinterpret
antibodi
titer
test
due
cross
reaction
differ
genus
chlamydia
particular
attent
c
trachomati
frequent
complic
urinari
tract
infect
acut
upper
respiratori
tract
infect
mostli
mild
moder
sever
although
may
becom
sever
categor
degre
sever
indic
determin
interpret
shown
tabl
indic
bodi
temperatur
white
blood
cell
count
crp
valu
ideal
indic
assess
day
day
prior
commenc
clinic
trial
antimicrobi
agent
highest
valu
indic
day
select
gener
clinic
improv
observ
subsid
fever
lower
white
blood
cell
count
crp
valu
esr
may
also
use
indic
evalu
drug
efficaci
although
affect
condit
infect
alon
speed
recoveri
assess
evalu
drug
efficaci
precis
evalu
conduct
evalu
made
basi
clinic
microbiolog
assess
microbiolog
effect
equivoc
evalu
made
prioriti
basi
clinic
assess
sever
bacteri
infect
mycoplasma
chlamydia
infect
final
day
evalu
conduct
maximum
day
addit
evalu
patient
meet
inclus
criteria
compliant
regimen
submit
evalu
ontherapi
evalu
regimen
start
final
evalu
etiolog
agent
determin
drug
regim
endoftherapi
evalu
assess
posttherapi
evalu
done
least
day
complet
therapi
testofcur
evalu
follow
concept
use
evalu
presum
erad
bacteri
outcom
extrapol
clinic
outcom
condit
b
document
erad
absenc
etiolog
agent
cultur
specimen
regimen
c
persist
presenc
etiolog
pathogen
even
complet
cours
antimicrobi
agent
therapi
mic
trial
drug
well
standard
drug
assess
determin
resist
concern
pathogen
recurr
isol
origin
pathogen
cultur
testofcur
cultur
previou
cultur
neg
origin
pathogen
care
verifi
necessari
invivo
sensit
assess
compar
pattern
e
reduct
quantit
reduct
origin
pathogen
verifi
quantit
cultur
techniqu
f
partial
erad
disappear
one
microb
treatment
infect
involv
multipl
pathogen
import
confirm
involv
multipl
pathogen
evalu
g
superinfect
isol
pathogen
origin
pathogen
specimen
taken
patient
therapi
patient
sign
symptom
infect
patient
evalu
clinic
effect
trial
antimicrobi
agent
day
day
initi
therapi
outcom
may
categor
effect
ineffect
basi
standard
criteria
shown
tabl
acut
upper
respiratori
tract
infect
may
bacteri
nonbacteri
origin
henc
evalu
differ
standard
acut
bacteri
upper
respiratori
tract
infect
drug
may
evalu
effect
two
three
criteria
tabl
satisfi
third
one
worsen
drug
usual
given
day
initi
evalu
least
two
three
criteria
fulfil
drug
may
continu
anoth
day
maximum
fulfil
standard
period
indic
effect
treatment
contrari
failur
achiev
standard
time
point
indic
treatment
ineffect
drug
discontinu
anoth
appropri
antimicrobi
drug
start
without
delay
failur
pursu
evalu
reason
lead
conclus
evalu
possibl
b
acut
nonbacteri
upper
respiratori
tract
infect
mycoplasma
chlamydia
evalu
acut
nonbacteri
upper
respiratori
tract
infect
done
basi
standard
criteria
shown
tabl
drug
may
evalu
effect
five
three
four
five
criteria
satisfi
other
worsen
evalu
time
procedur
use
acut
bacteri
upper
respiratori
tract
infect
clinic
evalu
antimicrobi
agent
conduct
complet
therapi
describ
section
clinic
evalu
method
brief
subsect
effect
antimicrobi
agent
howev
sometim
posttherapi
evalu
conduct
defin
time
period
depend
patholog
pathogen
involv
instanc
acut
bacteri
mycoplasma
chlamydia
infect
initi
therapi
prove
effect
follow
recurr
thu
final
evalu
antimicrobi
agent
quit
difficult
therefor
import
continu
followup
examin
laboratori
test
defin
time
period
acut
upper
respiratori
tract
infect
posttherapi
followup
consid
appropri
describ
protocol
advanc
pneumonia
frequent
subject
clinic
evalu
new
antimicrobi
agent
section
deal
determin
ing
inclus
criteria
select
patient
appropri
evalu
set
evalu
standard
sever
diseas
efficaci
antimicrobi
drug
moreov
paramet
use
assess
determin
also
set
pneumonia
defin
acut
infect
pulmonari
parenchyma
associ
least
symptom
acut
infect
accompani
presenc
acut
infiltr
chest
radiograph
auscultatori
find
consist
pneumonia
alter
breath
sound
andor
local
rale
infecti
agent
involv
cover
wide
rang
aerob
anaerob
bacteria
mycoplasma
chlamydia
acid
fast
bacilli
well
virus
fungi
frequenc
etiolog
agent
vari
host
factor
age
underli
diseas
preval
agent
factor
type
speci
environment
factor
whether
infect
acquir
commun
hospit
set
pathogen
microb
discuss
guidanc
includ
gener
bacteria
pneumonia
aureu
h
influenza
k
pneumonia
p
aeruginosa
moraxella
legionella
mycoplasma
chlamydia
pneumonia
caus
pathogen
virus
fungu
acidfast
bacilli
need
evalu
complet
differ
diagnost
standard
standard
criteria
evalu
effect
new
agent
also
need
set
easi
identifi
etiolog
pathogen
pneumonia
particularli
commenc
antimicrobi
drug
previou
report
indic
identif
rate
less
therefor
import
concern
drug
cover
probabl
etiolog
pathogen
howev
compar
reliabl
predict
possibl
basi
care
examin
aforement
host
agent
environment
factor
close
monitor
clinic
condit
preval
age
purul
sputum
perform
appropri
test
peripher
white
blood
cell
count
chest
xray
gram
stain
smear
specimen
purul
sputum
drug
trial
macrolid
new
fluoroquinolon
reason
cover
spectrum
pathogen
h
influenza
k
pneumonia
well
mycoplasma
chlamydia
involv
communityacquir
infect
necessari
identifi
etiolog
pathogen
begin
treatment
identif
import
drug
lactam
target
bacteri
infect
cours
import
variou
cultur
test
serodiagnosi
surpass
case
quick
diagnosi
also
possibl
employ
molecular
biolog
techniqu
pcr
method
collect
appropri
specimen
select
cultur
method
final
proper
evalu
utmost
import
inclus
criteria
patient
diagnosi
pneumonia
base
standard
clinic
radiograph
microbiolog
criteria
patient
satisfi
least
follow
criteria
includ
evalu
trial
clinic
effect
new
antimicrobi
agent
confirm
presenc
new
infiltr
chest
xray
comput
tomographi
ct
scan
confirm
exist
inflammatori
condit
evidenc
increas
white
blood
cell
count
wbc
migrat
nucleu
left
stab
leukocyt
rais
crp
mgdl
increas
esr
two
criteria
satisfi
two
four
follow
condit
met
fever
cough
sputum
purul
natur
chest
pain
dyspnea
auscultatori
find
pulmonari
examin
rale
andor
evid
pulmonari
consolid
dull
percuss
bronchial
breath
sound
egophoni
microorgan
isol
specimen
respiratori
secret
gram
stain
semiquantit
cultur
suppli
qualiti
specimen
rais
possibl
correctli
determin
etiolog
agent
specimen
respiratori
secret
may
obtain
follow
mean
deep
expector
nasotrach
aspir
bronchoscopi
bronchoalveolar
lavag
protect
brush
sampl
transtrach
aspir
addit
compli
gener
exclus
criteria
applic
trial
patient
enrol
pneumonia
trial
exclud
follow
reason
patient
known
bronchial
obstruct
histori
postobstruct
pneumonia
exclud
patient
chronic
obstruct
pulmonari
diseas
patient
primari
lung
cancer
anoth
malign
metastat
lung
unless
studi
specif
design
patient
popul
patient
cystic
fibrosi
aid
known
suspect
pneumocysti
carinii
pneumonia
known
suspect
activ
tuberculosi
clinic
effect
trial
drug
larg
influenc
sever
pneumonia
patient
condit
evalu
basi
sever
infect
sever
underli
diseas
andor
complic
sever
pneumonia
may
evalu
basi
standard
criteria
bodi
temperatur
chest
xray
find
peripher
white
blood
cell
count
crp
shown
tabl
criteria
evalu
sever
infect
assess
day
day
commenc
therapi
higher
valu
two
select
difficult
rigidli
restrict
criteria
mild
moder
sever
infect
even
white
blood
cell
count
less
nucleu
neutrophil
stab
leukocyt
migrat
left
case
evalu
exceed
mild
standard
addit
underli
diseas
factor
hematolog
disord
liver
diseas
also
affect
white
blood
cell
count
also
taken
consider
evalu
sever
pneumonia
chest
xray
import
tool
therefor
precis
interpret
find
also
necessari
score
system
develop
basi
number
infiltr
shadow
chest
xray
shown
tabl
fig
preexist
stromal
dysfunct
affect
score
includ
evalu
onset
cours
pneumonia
greatli
influenc
presenc
underli
diseas
extent
therefor
conduct
proper
evalu
clinic
effect
new
antimicrobi
agent
factor
critic
monitor
basi
standard
criteria
list
mild
effect
onset
pneumonia
cours
high
blood
pressur
hyperlipidemia
mild
liver
dysfunct
tabl
score
criteria
pneumonia
basi
chest
radiograph
find
area
involv
area
involv
score
abnorm
infiltr
small
infiltr
limit
one
intercost
site
infiltr
involv
one
lung
infiltr
involv
one
lung
infiltr
involv
one
lung
infiltr
involv
almost
one
entir
lung
infiltr
involv
almost
complet
lung
tabl
explan
score
moder
possibl
affect
onset
cours
pneumonia
magnitud
expect
sever
mild
chronic
obstruct
pulmonari
diseas
well
control
diabet
chronic
nephriti
sever
affect
onset
cours
pneumonia
significantli
well
effect
treatment
connect
tissu
diseas
leukemia
malign
diseas
particularli
advanc
stage
congest
heart
failur
chronic
airway
diseas
respiratori
insuffici
sever
pneumonia
sever
underli
diseas
complic
evalu
combin
conduct
proper
evalu
sever
patient
condit
clinic
effect
atimicrobi
agent
may
affect
consider
sever
patient
condit
thu
care
analysi
factor
mandatori
even
though
sever
detect
gener
bacteri
cultur
pathogen
encount
quit
often
trial
target
pneumonia
therefor
import
identifi
use
special
media
select
media
serolog
test
evalu
criteria
serolog
test
set
beforehand
far
mycoplasma
detect
concern
antibodi
titer
pair
test
sampl
taken
onset
diseas
convalesc
stage
show
fourfold
higher
increas
singl
sampl
titer
estim
cf
antibodi
titer
ha
antibodi
titer
time
time
higher
respect
similarli
diagnosi
chlamydia
pneumonia
may
made
cf
antibodi
titer
show
fourfold
higher
increas
pair
test
sampl
time
higher
singl
test
sampl
cold
agglutin
titer
rise
simultan
limit
valu
also
increas
due
factor
pneumonia
patient
etiolog
agent
isol
identifi
examin
day
day
onset
day
complet
treatment
maximum
day
evalu
conduct
basi
standard
criteria
describ
section
clinic
evalu
new
antimicrobi
agent
acut
respiratori
tract
infect
subsect
standard
efficaci
evalu
standard
evalu
microbiolog
outcom
clinic
outcom
treatment
new
antimicrobi
drug
evalu
basi
comparison
patient
baselin
sign
symptom
laboratori
paramet
later
stage
result
evalu
may
express
effect
ineffect
evalu
possibl
describ
tabl
evalu
undertaken
day
day
begin
antimicrobi
drug
therapi
usual
drug
discontinu
day
treatment
howev
result
assess
standard
criteria
may
avail
within
day
particularli
sever
pneumonia
pneumonia
accompani
underli
diseas
moder
sever
complic
situat
drug
may
continu
long
day
provid
trend
improv
observ
indic
improv
chest
xray
crp
valu
drug
may
consid
effect
resolut
sign
infect
mild
moder
degre
patient
condit
may
evalu
sever
provid
parallel
sever
underli
diseas
condit
complic
exist
patient
includ
usual
trial
evalu
antimicrobi
drug
studi
special
trial
set
bold
entri
tabl
efficaci
new
antimicrobi
drug
evalu
basi
microbiolog
clinic
outcom
determin
etiolog
agent
pneumonia
patient
quit
difficult
particularli
patient
good
sampl
respiratori
secret
avail
mani
patient
particular
earli
stage
pneumonia
expector
purul
sputum
ineffici
isol
etiolog
agent
possibl
import
identifi
follow
cours
caus
pathogen
order
evalu
clinic
effect
new
antimicrobi
agent
therefor
effort
made
facilit
expector
measur
infus
physiolog
salin
case
pneumonia
blood
cultur
use
identifi
etiolog
agent
pneumonia
aureu
anoth
factor
make
isol
etiolog
agent
pneumonia
difficult
trial
pretreat
form
antimicrobi
drug
therefor
patient
receiv
antimicrobi
drug
sinc
onset
diseas
includ
trial
special
attent
given
specif
pathogen
legionella
mycoplasma
chlamydia
bold
entri
indic
patient
studi
special
trial
set
symptom
pneumonia
improv
lack
progress
abnorm
chest
radiograph
patient
accompani
underli
diseas
complic
complet
resolut
achiev
standard
criteria
satisfi
particular
crp
valu
bodi
temperatur
day
patient
necessari
provid
object
proof
improv
treatment
evalu
drug
effect
compar
record
prior
onset
pneumonia
treatment
clinic
effect
studi
drug
evalu
earli
day
commenc
treatment
speed
clinic
recoveri
also
consid
combin
trend
improv
standard
criteria
absent
next
evalu
day
necessari
instead
drug
discontinu
administr
appropri
antimicrobi
agent
initi
evalu
clinic
effect
new
antimicrobi
agent
usual
complet
along
complet
treatment
regim
howev
posttherapi
followup
observ
may
necessari
particular
patient
depend
patholog
pathogen
organ
concern
exampl
drug
may
evalu
effect
initi
patient
sever
pneumonia
underli
diseas
mycoplasma
pneumonia
chlamydia
pneumonia
infect
may
recar
pathogen
subsequ
stage
therefor
followup
observ
defin
period
time
import
rule
possibl
period
consid
adequ
followup
evalu
pneumonia
time
evalu
final
evalu
new
antimicrobi
agent
econom
aspect
drug
also
assess
conjunct
efficaci
safeti
trial
drug
exhibit
equal
efficaci
similar
exist
drug
fewer
advers
reaction
moreov
econom
evalu
superior
exist
drug
howev
standard
criteria
specif
method
evalu
must
mention
protocol
advanc
acut
exacerb
chronic
pulmonari
diseas
almost
alway
attribut
infect
pathogen
often
bacteria
treatabl
antimicrobi
agent
section
deal
defin
guidelin
select
patient
evalu
sever
patient
condit
evalu
efficaci
trial
drug
symptom
acut
aggrav
infect
occur
patient
chronic
pulmonari
diseas
impair
airway
protect
chronic
bronchiti
chronic
pulmonari
emphysema
bronchiectasi
diffus
panbronchiol
administr
antimicrobi
initi
earliest
possibl
time
sometim
acut
exacerb
due
underli
diseas
complic
rather
infect
acut
exacerb
due
bacteri
caus
character
increas
cough
sputum
product
dyspnea
addit
develop
sputum
purul
amount
sputum
degre
purul
purul
mucopurul
mucoid
good
indic
clinic
assess
suitabl
specimen
respiratori
secret
essenti
identif
etiolog
pathogen
isol
caus
organ
necessari
proper
evalu
efficaci
studi
drug
commonli
encount
microorgan
acut
exacerb
chronic
pulmonari
diseas
h
influenza
pneumonia
includ
streptococci
moraxella
branhamella
catarrhali
aureu
well
k
pneumonia
pseudomona
anaerob
bacteria
mani
microb
establish
involv
communityacquir
infect
except
methicillinresist
staphylococcu
aureu
mrsa
gram
neg
bacteria
pseudomona
contrast
mrsa
pseudomona
isol
patient
long
histori
persist
infect
compar
sever
underli
respiratori
diseas
improv
symptom
sign
mainli
consid
design
convent
evalu
standard
clinic
effect
antimicrobi
agent
wherea
effect
drug
etiolog
agent
given
import
even
though
deterior
clinic
condit
assess
increas
bodi
temperatur
peripher
white
blood
cell
count
crp
valu
absenc
fever
increas
white
blood
cell
count
rule
possibl
acut
exacerb
analysi
convent
evalu
data
shown
patient
fever
increas
white
blood
cell
count
observ
patient
therefor
import
conduct
evalu
microbiolog
effect
along
clinic
effect
better
outcom
esr
chest
xray
arteri
blood
ga
analysi
may
also
use
addit
tool
patient
enrol
studi
evalu
clinic
effect
new
antimicrobi
agent
clinic
diagnosi
chronic
pulmonari
diseas
base
histori
physic
examin
radiograph
examin
also
necessari
exclud
presenc
chronic
bronchiti
pneumonia
standard
criteria
select
patient
follow
onset
cough
sputum
increas
volum
sputum
andor
worsen
degre
purul
b
increas
crp
mgdl
valu
exce
facil
maximum
valu
follow
criteria
also
satisfi
two
criteria
fulfil
c
microbiolog
confirm
etiolog
pathogen
gram
stain
examin
isol
cultur
suitabl
specimen
specimen
consid
adequ
contain
squamou
epitheli
cell
wbc
per
field
magnif
fever
e
increas
peripher
white
blood
cell
count
valu
exce
facil
maximum
valu
sever
patient
condit
acut
exacerb
chronic
pulmonari
diseas
affect
sever
underli
diseas
complic
well
sever
infect
respiratori
function
reserv
alreadi
compromis
patient
even
absenc
infect
therefor
microbi
invas
worsen
function
abil
due
inflamm
airway
underli
diseas
complic
rang
mild
sever
form
littl
major
effect
respect
onset
cours
infect
special
attent
given
patient
respiratori
cardiac
insuffici
prone
worsen
easili
common
indic
assess
sever
infect
includ
fever
peripher
white
blood
cell
count
crp
valu
instanc
case
aggrav
persist
pseudomona
infect
patient
sever
underli
lung
diseas
sever
diffus
panbronchiol
bronchiectasi
old
lung
tuberculosi
tracheostomi
indic
show
signific
chang
dyspnea
may
becom
sever
sever
infect
acut
exacerb
chronic
pulmonari
diseas
may
evalu
basi
fever
peripher
white
blood
cell
count
crp
valu
shown
tabl
three
criteria
assess
day
day
prior
onset
treatment
higher
valu
two
select
evalu
howev
presum
indic
evalu
caus
underli
diseas
complic
underli
diseas
complic
may
categor
mild
moder
sever
mild
patient
mild
chronic
pulmonari
diseas
chronic
bronchiti
chronic
pulmonari
emphysema
diffus
panbronchiol
uncompl
heart
diseas
complic
affect
cours
infect
mild
hypertens
hyperlipidemia
liver
dysfunct
moder
patient
moder
chronic
pulmonari
diseas
mild
latent
cardiac
insuffici
complic
expect
major
effect
infect
control
diabet
chronic
nephriti
sever
patient
chronic
pulmonari
diseas
accompani
respiratori
insuffici
cardiac
insuffici
complic
affect
cours
infect
serious
uncontrol
diabet
includ
ketoacidosi
connect
tissu
diseas
tracheostomi
artifici
respir
advanc
malign
sever
infect
becom
intract
patient
sever
underli
lung
diseas
andor
complic
major
studi
popul
belong
categori
appropri
evalu
trial
drug
may
possibl
sever
patient
condit
evalu
basi
combin
evalu
sever
infect
sever
underli
diseas
complic
shown
tabl
sever
patient
condit
larg
affect
cours
infect
appropri
analysi
necessari
better
outcom
trial
accord
standard
criteria
assess
sever
patient
condit
patient
mild
moder
infect
may
evalu
sever
infect
accompani
sever
underli
diseas
complic
subject
usual
appropri
clinic
evalu
antimicrobi
agent
bold
entri
indic
patient
studi
special
trial
set
efficaci
evalu
standard
determin
etiolog
agent
necessari
evalu
characterist
antiinfect
drug
premis
understand
etiolog
agent
known
clinic
find
combin
chang
cours
etiolog
agent
investig
evalu
criteria
order
determin
extent
invitro
antimicrobi
activ
reflect
actual
treatment
infect
thu
evalu
microbiolog
effect
well
clinic
effect
conduct
day
commenc
treatment
treatment
complet
usual
day
maximum
day
first
evalu
day
give
impress
trend
effect
studi
drug
speed
recoveri
help
decid
whether
continu
drug
identif
microb
gram
stain
smear
specimen
particularli
use
commenc
antimicrobi
agent
treatment
isol
etiolog
agent
specimen
respiratori
secret
larg
depend
qualiti
specimen
purul
sputum
specimen
contain
wbc
per
field
squamou
epitheli
cell
magnif
may
provid
good
opportun
determin
caus
pathogen
gram
stain
cultur
gross
appear
sputum
contain
yellow
green
portion
use
test
care
taken
avoid
falseneg
result
often
obtain
examin
mucoid
sputum
contain
lot
saliva
mucoid
sputum
may
expector
even
stabl
condit
without
infect
patient
chronic
bronchiti
chronic
pulmonari
emphysema
increas
sputum
volum
sign
exacerb
infect
sputum
mucoid
infect
viral
origin
target
infect
evalu
antimicrobi
agent
therapi
therefor
includ
evalu
studi
inadequ
ineffici
suppli
specimen
transtrach
aspir
bronchoscopi
may
help
obtain
qualiti
sampl
respiratori
exud
select
appropri
cultur
medium
also
import
correct
identif
caus
agent
usual
almost
aerob
bacteria
isol
blood
agar
chocol
agar
medium
serolog
diagnost
method
help
patient
acut
exacerb
chronic
lung
diseas
contrast
pneumonia
evalu
microbiolog
outcom
may
conduct
use
similar
standard
procedur
describ
section
clinic
evalu
new
antimicrobi
agent
acut
respiratori
tract
infect
subsect
standard
efficaci
evalu
standard
evalu
microbiolog
outcom
evalu
efficaci
antimicrobi
agent
invitro
mic
minimum
inhibitori
concentr
mbc
minimum
bacteri
concentr
may
examin
mbc
also
provid
inform
speed
microbiolog
recoveri
lesion
exampl
specimen
sputum
collect
patient
day
commenc
trial
antimicrobi
agent
subject
mbc
investig
give
compar
inform
effect
trial
drug
well
speed
elimin
caus
pathogen
thu
quantit
inform
microb
along
result
gram
stain
cultur
help
understand
natur
kinet
infect
addit
use
inform
may
also
obtain
measur
concentr
trial
drug
blood
lesion
effect
new
antimicrobi
agent
may
shown
observ
follow
improv
improv
cough
reduct
sputum
volum
low
almost
half
adiministr
antimicrobi
agent
chang
sputum
purul
mucopurul
mucoid
mucopurul
mucoid
return
bodi
temperatur
normal
fever
treatment
fever
observ
patient
previou
clinic
trial
studi
antimicrobi
drug
acut
exacerb
chronic
lung
diseas
report
patient
bodi
temperatur
lower
addit
determin
peripher
white
blood
cell
count
crp
also
import
indic
evalu
crp
sensit
indic
track
effect
chemotherapi
trial
drug
may
evalu
effect
crp
valu
show
improv
becom
neg
except
observ
even
though
peripher
white
blood
cell
count
import
indic
evalu
clinic
effect
new
antimicrobi
agent
previou
trial
shown
wbc
count
increas
patient
approxim
chronic
pulmonari
diseas
similarli
certain
patient
show
clearcut
increas
crp
valu
mgdl
approxim
patient
patient
therefor
care
attent
paid
clinic
criteria
cough
sputum
evalu
addit
peripher
wbc
count
crp
valu
may
fluctuat
due
underli
condit
connect
tissu
diseas
evalu
trial
drug
patient
must
conduct
great
care
standard
criteria
evalu
clinic
effect
new
antimicrobi
drug
patient
chronic
pulmonari
diseas
summar
tabl
shown
tabl
drug
would
consid
effect
improv
cough
sputum
condit
addit
two
remain
three
criteria
satisfi
one
worsen
failur
meet
standard
criteria
would
evalu
trial
drug
ineffect
remark
evalu
possibl
appli
standard
criteria
beyond
scope
evalu
reason
efficaci
evalu
trial
drug
conduct
present
report
constitut
attempt
improv
modifi
exist
clinic
evalu
method
new
antimicrobi
agent
treat
respiratori
infect
draft
construct
basi
analyz
larg
amount
materi
collect
year
incorpor
intern
extern
factor
concern
present
evalu
method
newli
suggest
standard
criteria
clinic
evalu
new
antimicrobi
drug
expect
practic
properli
hereupon
subject
improv
necessari
volum
fundament
materi
upon
evalu
standard
set
enorm
discuss
elsewher
beyond
scope
report
inform
publish
journal
societi
respect
concern
committe
tabl
evalu
effect
new
antimicrobi
agent
patient
acut
exacerb
chronic
pulmonari
diseas
criteria
effect
cough
improv
term
sever
sputum
improv
degre
purul
reduct
amount
b
crp
improv
less
previou
valu
bodi
temperatur
improv
white
blood
cell
improv
count
facil
normal
rang
chang
purul
mucopurul
mucoid
chang
mucopurul
mucoid
b
reduct
less
quantit
measur
day
h
day
commenc
drug
administr
evalu
clinic
effect
drug
administ
day
base
standard
criteria
may
help
assess
speed
improv
clinic
microbiolog
statu
patient
satisfi
efficaci
criteria
day
administr
antimicrobi
agent
agent
may
evalu
extrem
effect
gener
evalu
day
treatment
provid
reason
suffici
inform
justifi
defermin
efficaci
trial
drug
drug
effect
etiolog
agent
would
erad
time
residu
sign
symptom
would
reach
baselin
level
particular
patient
stabl
state
ie
exacerb
chronic
pulmonari
diseas
sometim
treatment
extend
anoth
day
improv
sign
symptom
enough
discontinu
drug
particular
attent
paid
patient
receiv
long
term
antimicrobi
therapi
term
microbi
substitut
develop
resist
drug
suspect
ineffect
discontinu
immedi
switch
suitabl
drug
delay
administr
new
antimicrobi
drug
evalu
clinic
effect
patient
acut
exacerb
chronic
pulmonari
diseas
may
result
erad
etiolog
agent
henc
drug
may
evalu
effect
sometim
recurr
reinfect
may
follow
termin
treatment
therefor
import
conduct
followup
examin
defin
time
period
cessat
drug
precis
schedul
mention
protocol
advanc
usual
posttherapi
followup
week
consid
adequ
rule
possibl
recurr
reinfect
laboratori
test
microscopi
stain
smear
cultur
particularli
quantit
assess
microb
respiratori
secret
use
precis
evalu
recurr
reinfect
posttherapi
period
